The Immuno-oncology (I-O) Focus on VJHemOnc is supported by Johnson & Johnson. This supporter has no influence over the production of the content.
Therapeutic and prophylactic vaccines are an exciting upcoming area in hematology-oncology. In solid tumors, there have been many clinical trials1-6 and several approvals7,8. Now moving forward in the hemonc space, vaccines offer the prospect of long-term responses with limited side effects9.
Personalized dendritic cell vaccines for acute leukemias and multiple myeloma have yielded promising results in clinical trials10-13. There are also vaccines in trials for chronic lymphocytic leukemia14,15, chronic myeloid leukemia and other myeloid malignancies16-19, myeloproliferative neoplasms20, and myelodysplastic syndromes21. Another personalized vaccine has been investigated for the treatment of follicular lymphoma, mantle cell lymphoma and Waldenstrom’s macroglobulinemia22,23.
- Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014 Sep; 11(9): 509-24.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012 Dec 4. Identifier NCT01740297. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01740297
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Mar 17. Identifier NCT02390063. Vaccination in Prostate Cancer (VANCE); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02390063
- Tanyi JL, Bobisse S, Ophir E, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018 Apr 11; 10(436).
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Jan 28. Identifier NCT02348320. Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02348320
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 Mar 20. Identifier NCT01814813. Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery; [cited 2018 Aug 29]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01814813
- FDA.gov [Internet]. PROVENGE (sipuleucel-T); [updated 2018 Feb 20]; [cited 2018 Aug 29]. Available from: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm
- FDA.gov [Internet]. Human Papillomavirus Vaccine; [updated 2018 Feb 20]; [cited 2018 Aug 29]. Available from: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678.htm
- VJHemOnc.com [Internet]. Using vaccines to impart a long-term response in lenalidomide-treated MM; c2017-06; [cited 2018 Aug 29]. Available from: https://www.vjhemonc.com/video/ssaigcq_dkk-using-vaccines-to-impart-a-long-term-response-in-lenalidomide-treated-mm/
- VJHemOnc.com [Internet]. Personalized dendritic cell vaccine for acute leukemia and multiple myeloma; c2018-04; [cited 2018 Aug 29]. Available from: https://www.vjhemonc.com/video/9zooz_nhvx8-personalized-dendritic-cell-vaccine-for-acute-leukemia-and-multiple-myeloma/
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2016 Apr 5. Identifier NCT02728102. Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02728102
- Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017 Oct; 130(15): 1713-1721.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2004 May 21. Identifier NCT00002787. Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00002787
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 Nov 5. Identifier NCT01976520. Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01976520
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 May 11. Identifier NCT01351896. Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01351896
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 Sep 7. Identifier NCT02543749. DC Vaccination in CML; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02543749
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2007 Apr 27. Identifier NCT00466726. Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (CML0206); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00466726
- Ottensmeier C, Bowers M, Hamid D, et al. Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). Efficacy Mech Eval. 2016 Apr.
- Qazilbash MH, Wieder E, Thall PF, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 Mar; 31(3) :697-704.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 June 25. Identifier NCT03566446. CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms; [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03566446
- Griffiths EA, Srivastava P, Matsuzaki J, et al. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clin Cancer Res. 2018 Mar 1; 24(5): 1019-1029.
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2004 Sep 17. Identifier NCT00091676. Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (BiovaxID); [cited 2018 Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT00091676
- Neelapu SS, Kwak LW, Kobrin CB. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005 Sep; 11(9): 986-91.
Sorry, no posts matched your criteria.